Physician profile
Joseph C Empey
NPI 1205058294
$8,134.78
in general payments reported to CMS, 2019-2025
38 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 75% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $950 · 2021: $1,332 · 2022: $1,317 · 2023: $1,396 · 2024: $1,096 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,888.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,501.49 | 2019-2025 | Artisan, Coveredge 32, Intracept |
| Abbvie INC. | $889.28 | 2022-2025 | |
| Nevro Corp. | $730.69 | 2019-2023 | Senza |
| Abbott Laboratories | $702.82 | 2019-2022 | |
| Relievant Medsystems, INC. | $335.71 | 2020-2023 | Intracept |
| Lundbeck LLC | $314.91 | 2020-2025 | Vyepti |
| Pfizer INC. | $284.24 | 2023-2025 | |
| Allergan, INC. | $274.70 | 2019-2022 | |
| Nalu Medical, INC. | $200.29 | 2021-2023 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.05 | 2019-2024 | Relistor |
| Mml US, INC. | $175.59 | 2024 | Reactiv8 |
| Teva Pharmaceuticals USA, INC. | $175.43 | 2019-2024 | Ajovy |
| Collegium Pharmaceutical, INC. | $140.63 | 2019-2024 | Xtampza, Belbuca |
| Grt US Holding, INC. | $125.31 | 2020-2022 | |
| Medtronic, INC. | $118.37 | 2023-2025 | Intellis Adaptivestim, Vanta Adaptivestim |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $100.45 | 2023-2025 | Qutenza |
| Vertos Medical, INC. | $95.69 | 2023-2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.17 | 2022 | |
| Amgen INC. | $87.24 | 2020-2021 | |
| Radius Health, INC. | $80.23 | 2021 | |
| Spr Therapeutics, INC | $73.70 | 2022-2024 | Sprint Pns System |
| Lilly USA, LLC | $62.92 | 2020-2021 | |
| Redhill Biopharma INC. | $46.77 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $36.84 | 2019-2021 | |
| Bioventus LLC | $35.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.58 | 2019 | |
| Stimwave Technologies Incorporated | $30.15 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $29.67 | 2021 | |
| Siemens Medical Solutions USA, INC. | $28.72 | 2023 | Magnetom Free.Max |
| Protega Pharmaceutials INC | $20.24 | 2025 | Roxybond |
| Medtronic Vascular, INC. | $19.64 | 2020 | |
| Si-Bone, INC. | $17.06 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.20 | 2025 | |
| Medtronic USA, INC. | $14.76 | 2020 | |
| Daiichi Sankyo INC. | $14.60 | 2019 | |
| Kaleo, INC. | $13.95 | 2019 | |
| Sentynl Therapeutics, INC. | $11.83 | 2019 | |
| Vertiflex, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Empey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.